Ipsen
France Funds $17M Cancer Profiling, Biomarker Effort
NEW YORK (GenomeWeb News) – The French government has provided €13.4 million ($17.4 million) to fund the Innovative MODels Initiative (IMODI), a partnership aimed at facilitating the development of new cancer treatments.
Rarecell's CTC/CTM Technology Chosen for Study into Prostate Cancer
NEW YORK (GenomeWeb News) – French biotechnology firm Rarecells today announced that Ipsen and Institut Gustave Roussy, has selected its ISET technology for a study into patients with prostate cancer.
Ipsen, BioMérieux Partner on Theranostics Approach to Cancer
The collaboration will leverage Ipsen's broad portfolio of compounds and BioMérieux's diagnostic tests and focus on prostate and breast cancers, neuroendocrine tumors, and pituitary tomors.
While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.
Among these is a deal between Dicerna Pharmaceuticals and Japan's Kyowa Hakko Kirin, which announced this week that they have expanded their drug-development partnership to include work in immunologic and inflammatory diseases.
Jul 22, 2010
Apr 1, 2010